<DOC>
	<DOCNO>NCT01056198</DOCNO>
	<brief_summary>This study test two different approach removal dead tissue surface wound .</brief_summary>
	<brief_title>Santyl vs. Sharp Debridement Diabetic Foot Wounds</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>The informed consent document must read , sign , date subject subject 's legally authorize representative conduct study procedure exams . In addition , informed consent document must sign date individual consent subject conduct Visit 1 . A photocopy sign informed consent document must provide subject , original sign document place subject 's chart . Subjects 18 year age old . Subjects may either sex race skin type provide skin color , opinion investigator , interfere study assessment . Willing make require study visit . Able follow instruction perform dress change home , , caregiver perform dressing change accord protocol . Willing use Darco ( orthopedic ) shoe offload device insole , appropriate , start day screen run followup phase . A history Type I Type II Diabetes Mellitus require insulin oral hypoglycemic medication normalize blood glucose level . A foot wound : Superficial , involve full skin thickness underlie tissue 0.5 cm2 10 cm2 measure surface area screen visit ( yet debrided ) Chronic , define open 30 day On neuropathic foot , define inability perceive 10 gram pressure use SemmesWeinstein 5.07 equivalent monofilament periwound area Adequately perfuse , define TcPO2 &gt; 40 mmHg ; toe pressure &gt; 40 mmHg , Doppler waveform consistent adequate flow foot ( biphasic triphasic waveform ) screen . Acceptable state health nutrition : Serum albumin ≥ 2.0 g/dL ( 20g/L ) Prealbumin level ≥ 15 mg/dL ( 0.15g/L ) . Per Screening lab chemistry† report : Alkaline phosphatase &lt; 500 U/L Alanine aminotransferase ( ALT ) &lt; 200 U/L Aspartate aminotransferase ( AST ) &lt; 175 U/L Serum total bilirubin &lt; 3.0 mg/dL Serum blood urea nitrogen ( BUN ) &lt; 75 mg/dL Serum creatinine 4.5 mg/dL HbA1c 12 % Per Screening lab hematology† report : Hemoglobin ( Hgb ) &gt; 8.0 g/dL White blood cell ( WBC ) &gt; 2.0 109/L Absolute neutrophil count &gt; 1.0 109/L Platelet count &gt; 50 109/L . Local laboratory use , range inclusion set base Healthpoint Data Management range . Refer Appendix 18.1.2 . Contraindications hypersensitivity use study medication component ( refer product label ) . Target wound require debridement , cover dry eschar . Uncontrolled bleed disorder . Untreated cellulitis extend &gt; 2 cm around target wound , untreated lymphangitic streaking , spread beneath superficial fascia , deeptissue abscess , gangrene , infection muscle , tendon , joint bone . Infection patient systemic toxicity metabolic instability ( e.g. , fever , chill , tachycardia , hypotension , confusion , vomit , leukocytosis , acidosis , severe hyperglycemia , azotemia ) . Any follow : Target wound tunnel per probe visual assessment Osteomyelitis target foot wound probe bone Target wound heel Target wound Charcot deformity offload . Diagnosis chronic granulomatous disease , leukocyte adhesion defect severe neutropenia Treatment follow : Systemic corticosteroid Immunosuppressive agent ( ) Chemotherapeutic agent ( ) Antiviral agent ( ) Plateletderived growth factor Living skin equivalent Dermal substitute Radiation therapy target low extremity within 30 day prior sign inform consent document . Currently systemic antibiotic therapy Any medical condition judge Medical Monitor and/or Investigator cause study detrimental subject ( specify reason screen failure applies ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Diabetic Foot Ulcers</keyword>
	<keyword>Diabetic Foot Wounds</keyword>
</DOC>